Accrol Group Holdings plc (the “Company” or “Accrol”), the AIM-listed leading independent tissue converter, is pleased to announce that certain directors of Accrol have, pursuant to the Placing (as described in the Company's announcement of 20 November 2017 titled “Proposed Placing of £18m and Lifting of Suspension”), in aggregate purchased 400,000 ordinary shares of £0.001 each (“Ordinary Shares”) at a price of 50p per Ordinary Share as set out below….